EUPRAXIA PHARMACEUTICALS INC.(EPRX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
EPRX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for EUPRAXIA PHARMACEUTICALS INC. (EPRX), a Healthcare sector company. EPRX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (FY 2025), EUPRAXIA PHARMACEUTICALS INC. reports net income of $-38.6M, free cash flow of $-28.6M. Top institutional holders of EPRX by reported 13-F value include Affinity Asset Advisors,, BALYASNY ASSET MANAGEMENT L.P., Vivo Capital,, based on the most recent SEC filings. EPRX trades on the Nasdaq exchange and files with the SEC under CIK 1581178. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EPRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for EUPRAXIA PHARMACEUTICALS INC. directly from SEC EDGAR.
Revenue
FY 2025
$0.00
Net Income
FY 2025
$-38.6M
Free Cash Flow
FY 2025
$-28.6M
Get alerted when EPRX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for EUPRAXIA PHARMACEUTICALS INC. including:
Top Institutional Holders of EPRX
Affinity Asset Advisors, LLC
$11.5M1,589,005 shBALYASNY ASSET MANAGEMENT L.P.
$9.8M1,350,000 shVivo Capital, LLC
$9.8M1,350,000 shIkarian Capital, LLC
$8.8M1,214,741 shGREAT POINT PARTNERS LLC
$8.7M1,200,000 shSCOTIA CAPITAL INC.
$7.2M1,342,178 shPoint72 Asset Management, L.P.
$7.0M967,575 shUBS Group AG
$5.5M762,635 shRedmile Group, LLC
$5.1M700,000 shRubric Capital Management LP
$5.0M691,170 sh
| Fund | Value | Shares |
|---|---|---|
| Affinity Asset Advisors, LLC | $11.5M | 1,589,005 |
| BALYASNY ASSET MANAGEMENT L.P. | $9.8M | 1,350,000 |
| Vivo Capital, LLC | $9.8M | 1,350,000 |
| Ikarian Capital, LLC | $8.8M | 1,214,741 |
| GREAT POINT PARTNERS LLC | $8.7M | 1,200,000 |
| SCOTIA CAPITAL INC. | $7.2M | 1,342,178 |
| Point72 Asset Management, L.P. | $7.0M | 967,575 |
| UBS Group AG | $5.5M | 762,635 |
| Redmile Group, LLC | $5.1M | 700,000 |
| Rubric Capital Management LP | $5.0M | 691,170 |
More Healthcare Companies
View all Healthcare →Put EPRX on your watchlist
Track score changes the day EUPRAXIA PHARMACEUTICALS INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is EPRX a good stock to buy?
13F Pro's AI-powered analysis of EUPRAXIA PHARMACEUTICALS INC. (EPRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for EPRX are available on the EPRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own EPRX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling EPRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of EUPRAXIA PHARMACEUTICALS INC.'s investment landscape.